Search

Your search keyword '"Garrido Lopez P"' showing total 111 results

Search Constraints

Start Over You searched for: Author "Garrido Lopez P" Remove constraint Author: "Garrido Lopez P"
111 results on '"Garrido Lopez P"'

Search Results

1. VideoRun2D: Cost-Effective Markerless Motion Capture for Sprint Biomechanics

4. 1038P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: preliminary analysis for first-line (1L) treatment of non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN)

5. Maternal and neonatal outcomes after caesarean delivery in the African Surgical Outcomes Study: a 7-day prospective observational cohort study

6. 58O Real-world overall survival (OS) with durvalumab (D) after chemoradiotherapy (CRT) in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC): Interim analysis from the PACIFIC-R study

7. European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment:Cardio-oncology quality indicators

8. LBA4 CANOPY-N: A phase II study of canakinumab (CAN) or pembrolizumab (PEM), alone or in combination, as neoadjuvant therapy in patients (pts) with resectable stage Ib–IIIa non-small cell lung cancer (NSCLC)

9. European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment

10. 1189TiP Phase II study of anti-TIGIT GSK4428859A (GSK’859A)/EOS-448 + anti-CD96 GSK6097608 (GSK’608) + anti-PD-1 dostarlimab in non-small cell lung cancer (NSCLC)

11. 24P Preliminary data on INHERITY LC: Germline mutations of a cohort of selected non-small cell lung cancer (NSCLC) patients

13. 1010P Assessment of early resistance mechanisms to first-line osimertinib in EGFR-mutant NSCLC using spatial transcriptomics

14. 1849P Clinical predictors of long-term responses to immune checkpoint inhibitors (ICI) in a multi-tumor cohort

16. 1295P EP0031 a next-generation selective RET inhibitor (SRI): Correlation of molecular and clinical responses in patients with RET alteration positive solid tumours naïve to or following prior SRI

17. 1247P Radiotherapy (RT) patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients (pts) with Stage III unresectable non-small cell lung cancer (UR-NSCLC) treated with durvalumab (D) after chemoradiotherapy (CRT)

19. 1063P Influence of infusion timing on the outcomes of immunotherapy in a multi-tumor cohort

21. 1117P Mutational landscape of large cell neuroendocrine lung carcinoma: Molecular characterization using next generation sequencing

22. 572P Potential impact of molecularly-selected treatment in patients with endocrine neoplasms at a tertiary university hospital

23. 1509TiP The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor

24. 1066P Negative impact of steroids on the efficacy of immunotherapy in a multi-tumor cohort of patients: time and dose-dependent

25. European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment

26. Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline

27. 1246P Hybrid capture-based assays in primary diagnostics of NSCLC patients: Results from the NEOlung study

28. 1288P Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline

29. 1744P COVID-19 in cancer patients: Risk factors for the development of severe clinical event (SCE)

30. LBA70_PR The impact of COVID-19 on oncology professionals: Initial results of the ESMO resilience task force survey collaboration

31. Preliminary results from phase Ib study of spartalizumab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)

32. Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study

33. An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer

35. Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

36. LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients

37. Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer

38. Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)

39. Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)

40. Multicenter, nonrandomized, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy: results in malignant pleural mesothelioma (MPM)

43. The Lung Immune Prognostic Index (LIPI), a predictive score for immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) patients

46. 1171P - Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

49. 121P - LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients

50. 1616O - Multicenter, nonrandomized, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy: results in malignant pleural mesothelioma (MPM)

Catalog

Books, media, physical & digital resources